Drug
Raludotatug Deruxtecan
Raludotatug Deruxtecan: highest development phase Phase 2, developed by Merck. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Raludotatug Deruxtecan NCT06780085 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| Raludotatug Deruxtecan (R-DXd) NCT06864169 | Phase 2 | Gastrointestinal Cancer |
| Raludotatug Deruxtecan NCT06843447 | Phase 1/2 | Ovarian Cancer Recurrent |
Latest
No recent events.
Follow Raludotatug Deruxtecan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.